Dadun/></a>
				</td>
				<td class= Dadun
   (New user)
Help  | Contact  |  Castellano English  
 

Dadun > Depósito Académico > CIMA (Centro de Investigación Médica Aplicada) > Área de Ciencias Cardiovasculares > Cardiopatía hipertensiva > DA - CIMA - Cardiovasculares - Cardiopatía hipertensiva - Artículos de Revista >

Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats
Authors: Diez, J. (Javier)
Panizo, A. (Ángel)
Hernandez, M. (Marta)
Galindo, M.F. (María F.)
Cenarruzabeitia, E. (Edurne)
Pardo-Mindan, F.J. (Francisco Javier)
Keywords: Angiotensin-Converting Enzyme Inhibitors/pharmacology
Hypertension/pathology
Isoquinolines/pharmacology
Muscle, Smooth, Vascular/drug effects
Proto-Oncogene Proteins c-myc/analysis
Tetrahydroisoquinolines
Issue Date: 1997
Publisher: Nature publishing group
Publisher version: http://dx.doi.org/10.1016/S0895-7061(97)00210-0
ISSN: 0895-7061
Citation: Diez J, Panizo A, Hernandez M, Galindo MF, Cenarruzabeitia E, Pardo Mindan FJ. Quinapril inhibits c-Myc expression and normalizes smooth muscle cell proliferation in spontaneously hypertensive rats. Am J Hypertens 1997 Oct;10(10 Pt 1):1147-1152.
Abstract
A number of data suggest that angiotensin II-dependent activation of the protooncogene c-myc participates in the proliferative response of smooth muscle cells (SMC) of rats with spontaneous hypertension (SHR). We therefore investigated the effects of chronic treatment with the angiotensin converting enzyme (ACE) inhibitor quinapril on the oncoprotein c-Myc and the proliferating cell nuclear antigen cyclin A in SMC of small intramyocardial arteries from the left ventricle of SHR. The expression of c-Myc and cyclin A was assessed by immunocytochemical analysis. The number of smooth muscle cells was assessed by morphometrical analysis. As compared to normotensive Wistar-Kyoto (WKY) rats, untreated SHR exhibited an increased percentages of cells expressing c-Myc (33% +/- 4% v 19% +/- 2%, mean +/- SEM, P < .005) and cyclin A (25 +/- 2 v 11% +/- 1%, P < .001). In quinapril-treated SHR compared with untreated SHR, we found decreased expression of c-Myc (22% +/- 2%, P < .005) and cyclin A (13% +/- 1%, P < .001). No significant differences were found between WKY rats and quinapril-treated SHR in the above parameters. Cyclin A was directly correlated with the number of SMCs in each group of rats. These results suggest that an enhanced expression of c-Myc may be involved in the increased proliferation seen in SMCs from small arteries of SHR. Quinapril administration normalizes proliferation in the SMCs of SHR, possibly by inhibiting the expression of the oncoprotein c-Myc and its effects on the cell cycle.
Permanent link: http://hdl.handle.net/10171/20105
Appears in Collections:DA - CIMA - Cardiovasculares - Cardiopatía hipertensiva - Artículos de Revista

Files in This Item:
File:  Am J Hypertens 10; 1147-1152.html
Description: 
Size:  34,08 kB
Format:  HTML
 View / Open 

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.